Inivata is a global clinical cancer genomics company utilising a proprietary, industry-leading liquid biopsy platform to transform patient care.
Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment.
Inivata's InVision™ liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians.
Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies. The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK.
CIC point of contact: Robert Tansley